The second Trump administration is planning changes that will impact the dental industry, and ADA and other outfits are concerned.
The FDA also approved suzetrigine, a non-opiod pain manager, and DSOs are expected to see a sizeable number of mergers and acquisitions over the next few years.
Please see full publication below for more information.
